Latest filing published 22 Dec 2022 for OncoCyte Corp.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Douglas T. Ross: trading record in brief
Douglas T. Ross (senior executive) discloses dealings in Insight Molecular Diagnostics Inc. to SEC (Form 4). We count 5 filings; the first trade dates from 11 December 2020 and the latest from 21 December 2022.
On the market, this insider has only ever bought: 1 purchase, €19k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 3 share grants. In 2022 alone, the filings show 1 purchase and no sales.
The record was last updated on 22 December 2022 with a share grant in Insight Molecular Diagnostics Inc. The last insider purchase was made public on 28 March 2022, 1,688 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Douglas T. Ross
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 213,797 shares0Common Stock, no par valueSEC:0001493152-22-036367:0
- 150,000 shares0Common Stock, no par valueSEC:0001493152-22-035991:0
- 150,000 shares0Common Stock, no par valueSEC:0001493152-22-023389:0
- 15,000 shares@ US$1.40100.0% of flowCommon Stock, no par valueSEC:0001493152-22-007931:0Canonical exit: 23 Jun 2022 (T+90)
4 of 4 declarations
